RECEIVED CENTRAL FAX CENTER

JUL 2 6 2006

Lindor the Deseased Destructor Ant of approx	U.8	. Patent and T	mdamark Office: L	through 07/31/2008. OMB 0851-0031 J.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995	Application Number	10/801,43		displays a valid OMB control number.
TRANSMITTAL	Filing Date	June 23, 2003 Fensome et a).		
FORM	First Named Inventor			
	Art Unit	1817		
(to be used for all correspondence after initial	Examiner Name	S. Hul		
	Altomey Docket Number	AHPWA24AUSA		
FORM NUMBER OF PAGES IN THIS SUBMISSION				
ENCLOSURES (Check all that apply) After Allowance Communication to TC				
Fee Transmittal Form Fee Attached	Drawing(s) Licensing-related Papers	\ <u> </u>		l Communication to Board eals and Interferences
Amendment/Reply After Final After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Petition Petition Petition Position to Convert to a Provisional Application Power of Attorney, Revocal Change of Correspondence Terminal Disclaimer Request for Refund CD. Number of CD(s) Landscape Table on C Remarks Customer No. 38199	Address	(Appea	Enclosure(s) (please Identify
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name				
HOWSON AND HOWSO	N J			
Signature Cather a Hodes Tr				
Printed name Cathy A. Kodroft				
Date 1-26-2006	7-26-2006 Reg. No. 33,980			
I hereby certify that this correspondence is sufficient postage as first class mail in an artific date shown below:		TO or depos	sited with the Un	
Signature	(Paloucell			
Typed or printed name Tracy U. Palovic	ıh .		Date	7-26-2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gethering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

JUL 2 6 2006

AHPWA24AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

: 10/601,438

Confirmation No.: 7149

Applicant

: Fensome et al.

Filed

: June 23, 2003

TC/A.U.

: 1617

Examiner

: S. Hui

Customer No.

: 38199

Title

: METHOD OF TREATING HORMONE-RELATED

CONDITIONS USING THIO-OXINDOLE DERIVATIVES

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE UNDER 35 USC § 121 AND AMENDMENT

Sir:

This paper is in response to the Office Action dated June 30, 2006 and issued for restriction purposes. Please enter the following elections, amendments, and remarks.

Elections begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 19 of this paper.

Certificate Under 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with sufficient postage as first class mail with or is being facsimile transmitted to the United States Patent and Trademark Office at:

P.O. Box 1450

Alexandria, VA 22313-1450. on <u>1-26-2706</u>

Signature TRACY U. PALOVICH

07/26/2006 08:51 FAX → USPTO ② 003/040

AHPWA24AUSA

ELECTIONS

Restriction Requirement

In response to elect the claims of one (1) of groups I-IV, Applicants hereby elect the claims of Group I, i.e., claims 1-23 drawn to a method of inducing contraception employing the compounds of Formula (I) and a selective estrogen receptor modulators (SERM).

Species Election Requirement

In response to the requirement to elect a single disclosed species, Applicants hereby elect 5-(2'-thioxospiro[cyclohexane-1,3'-[3H]indol]-5'-yl)-1-methyl-pyrrole-2-carbonitrile. Claims 1-7, 9, and 12-14 read on the outstanding species election.